News

March 20, 2026

Register today to join a short webinar organized by our Partner – OZ Biosciences. Use this opportunity to learn about our collaboration, mRNA platform, and listen to our Senior mRNA Scientist, Marcelina Bednarczyk, describing ExploCap and other cap analogs...

March 19, 2026

We are partnering at BioEurope Spring in Lisbon. ExploRNA Therapeutics will be represented by our Director of Business Development, Piotr Stępniak. Talk to Piotr and learn more about our capping technologies for the development of next-generation of mRNA and...

February 3, 2026

ExploRNA Therapeutics announces a strategic partnership with OZ Biosciences to broaden access to its next-generation RNA capping technology Warsaw, Poland – 03/02/2026 – ExploRNA Therapeutics, a Polish biotechnology company developing next-generation co-transcriptional RNA capping technologies (cap analogs) for high-performance...

January 29, 2026

We are pleased to share that ExploRNA Tx has recently secured patent protection in the United States, Japan, and at the European Patent Office (EPO) for an invention covering novel solutions targeting the 5’ end of mRNA, including novel 5’-end cap analogs—a key component of...

November 10, 2025

We are proud to announce that our team will join this year’s 13th International mRNA Health Conference in Berlin. Whether you are attending in person or virtually, check out our poster presented by Mirosław Śmietański, mRNA Team Lead, and...

September 23, 2025

If you are in Krakow this week, don’t miss this chance to hear our CEO, prof. Jacek Jemielity talk about the “New developments in mRNA technology” at the RNA Biology and Medicine mini-symposium organised by Małopolska Centre of Biotechnology...

September 22, 2025

We are proud to announce that this year our Founder and CEO, prof. Jacek Jemielity will receive “Stanislaw Kostanecki Medal” award for his extraordinary achievements in the field of organic chemistry from Polish Chemical Society. Jacek will receive the...

September 16, 2025

On 18-19 September in Munich, during a R&D Symposium organised by WACKER, our Senior mRNA Specialist, Marcelina Bednarczyk, PhD, will present a poster “AvantCap® Q line – novel tetranucleotide cap analogs with superior in vitro and in vivo potential”....

September 15, 2025

This week in Coronado, California, our team will participate in the 2nd Annual Meeting of Alliance for mRNA Medicines – ASCENT. Our Co-founder and Director of Research and Quality Development, Marek Baranowski will present our company, and our Director...

July 4, 2025

Unlock the full potential of your mRNA with ExploRNA’s Cap Analogs 5’ cap structure is a crucial element of every eukaryotic mRNA molecule. Beyond its well-known role in protecting mRNA against premature degradation and initiation of translation, it is...